Your browser doesn't support javascript.
loading
Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy.
Belov, Artur; Huang, Yin; Villa, Carlos H; Whitaker, Barbee I; Forshee, Richard; Anderson, Steven A; Eder, Anne; Verdun, Nicole; Joyner, Michael J; Wright, Scott R; Carter, Rickey E; Hung, Deborah T; Homer, Mary; Hoffman, Corey; Lauer, Michael; Marks, Peter.
Afiliação
  • Belov A; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Huang Y; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Villa CH; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Whitaker BI; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Forshee R; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Anderson SA; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Eder A; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Verdun N; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
  • Joyner MJ; Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Wright SR; Department of Cardiology and the Human Research Protection Program, Mayo Clinic, Rochester, Minnesota, USA.
  • Carter RE; Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
  • Hung DT; Infectious Disease and Microbiome Program, Broad Institute, Cambridge, Massachusetts, USA.
  • Homer M; Biomedical Advanced Research and Development Authority (BARDA), District of Columbia, Washington, USA.
  • Hoffman C; Biomedical Advanced Research and Development Authority (BARDA), District of Columbia, Washington, USA.
  • Lauer M; Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
  • Marks P; Center for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
Am J Hematol ; 97(6): 770-779, 2022 06 01.
Article em En | MEDLINE | ID: mdl-35303377
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos